AXOGEN INC. - COMMON STOCK

Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)

03 Sep 2024 04:00:00 By Nasdaq GlobeNewswire

Axogen, Inc. Announces New Leadership Appointments

08 Aug 2024 04:05:00 By Nasdaq GlobeNewswire

Axogen, Inc. Reports Second Quarter 2024 Financial Results

08 Aug 2024 04:00:01 By Nasdaq GlobeNewswire

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

23 Jul 2024 04:00:00 By Nasdaq GlobeNewswire

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

01 Jul 2024 04:00:00 By Nasdaq GlobeNewswire

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

24 Jun 2024 04:00:00 By Nasdaq GlobeNewswire

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

28 May 2024 13:30:00 By Nasdaq GlobeNewswire

Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®

16 May 2024 04:00:00 By Nasdaq GlobeNewswire

Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference

14 May 2024 04:00:00 By Nasdaq GlobeNewswire

Axogen, Inc Reports First Quarter 2024 Financial Results

02 May 2024 04:00:01 By Nasdaq GlobeNewswire

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

29 Apr 2024 13:50:00 By Nasdaq GlobeNewswire

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

16 Apr 2024 04:00:00 By Nasdaq GlobeNewswire

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

05 Mar 2024 04:00:00 By Nasdaq GlobeNewswire

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

13 Feb 2024 13:30:00 By Nasdaq GlobeNewswire

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

02 Feb 2024 13:15:00 By Nasdaq GlobeNewswire

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

18 Jan 2024 14:00:00 By Nasdaq GlobeNewswire

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

04 Jan 2024 13:45:00 By Nasdaq GlobeNewswire

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

04 Jan 2024 13:40:00 By Nasdaq GlobeNewswire

Axogen Announces Promotions on Research and Development Team

04 Jan 2024 13:35:00 By Nasdaq GlobeNewswire

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

26 Dec 2023 13:15:00 By Nasdaq GlobeNewswire